PTPRC and central nervous system cancer: PBDC reduction in dex-treated patients was even more evident when DC subsets were visualized in UMAP plots of viable CD45+/lin-/HLA-DR+ cells obtained from down-sampled and concatenated files of all blood samples of dex-treated and untreated glioma patients (Figure 1C).